Usefulness of Atorvastatin in Patients With Heart Failure Due to Inflammatory Dilated Cardiomyopathy and Elevated Cholesterol Levels
This study evaluated the safety, tolerability, and efficacy of statin therapy in patients with heart failure secondary to inflammatory dilated cardiomyopathy and moderately elevated low-density lipoprotein cholesterol levels. Seventy-four patients were randomized to receive atorvastatin 40 mg/day or...
Gespeichert in:
| Veröffentlicht in: | The American journal of cardiology 2006-03, Vol.97 (6), p.899-904 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 904 |
|---|---|
| container_issue | 6 |
| container_start_page | 899 |
| container_title | The American journal of cardiology |
| container_volume | 97 |
| creator | Wojnicz, Romuald Wilczek, Krzysztof Nowalany-Kozielska, Ewa Szyguła-Jurkiewicz, Bożena Nowak, Jolanta Poloński, Lech Dyrbuś, Krzysztof Badziński, Arkadiusz Mercik, Gabriela Zembala, Marian Wodniecki, Jan Rozek, Marius M. |
| description | This study evaluated the safety, tolerability, and efficacy of statin therapy in patients with heart failure secondary to inflammatory dilated cardiomyopathy and moderately elevated low-density lipoprotein cholesterol levels. Seventy-four patients were randomized to receive atorvastatin 40 mg/day or conventional treatment for heart failure. After 6 months of therapy, the predefined primary efficacy end point (an increase of >5% in the absolute left ventricular ejection fraction and ≥2 selected criteria by echocardiography and a decrease in New York Heart Association functional class) was significant in the statin-treated patients (p = 0.004). Among secondary efficacy parameters, the quality-of-life index showed a trend suggesting the benefit of statin therapy (p = 0.055). In conclusion, the results of this study demonstrate that treatment with atorvastatin in addition to standard therapy for heart failure may significantly improve clinical outcomes in this cohort of patients. |
| doi_str_mv | 10.1016/j.amjcard.2005.09.142 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67716438</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002914905021211</els_id><sourcerecordid>67716438</sourcerecordid><originalsourceid>FETCH-LOGICAL-c420t-e1fc5bd135393164eab848e5f2be246751d16d27d68d5ec367b0c2fc167c81373</originalsourceid><addsrcrecordid>eNqFkV-L1DAUxYMo7jj6EZQg6Ftr_rRp-yTL7K67MKAPLj6GNLllUtJmTNKBefeDm2UKC74IF5JLfudwyEHoPSUlJVR8GUs1jVoFUzJC6pJ0Ja3YC7ShbdMVtKP8JdoQQljR0aq7Qm9iHPNKaS1eoysq6jxdu0F_HiMMi5shRuwHfJ18OKmYVLIzzvMjX2BOEf-y6YDvQYWE75R1SwB8swBOHj_Mg1PTpLLyjG-sUwkM3uVg1k9nf1TpcMZqNvjWwenydvAOYoLgHd7DCVx8i14NykV4t55b9Hh3-3N3X-y_f3vYXe8LXTGSCqCDrntDec07TkUFqm-rFuqB9cAq0dTUUGFYY0RratBcND3RbNBUNLqlvOFb9Pniewz-95IzyMlGDc6pGfwSpWiabMvbDH78Bxz9EuacTTJOuOBVTrBF9QXSwccYYJDHYCcVzpIS-dSRHOXakXzqSJJO5o6y7sNqvvQTmGfVWkoGPq2Ailq5IahZ2_jMNYKJilWZ-3rh8hfCyUKQUee2NBgbQCdpvP1PlL8mE7NT</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>230363439</pqid></control><display><type>article</type><title>Usefulness of Atorvastatin in Patients With Heart Failure Due to Inflammatory Dilated Cardiomyopathy and Elevated Cholesterol Levels</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Wojnicz, Romuald ; Wilczek, Krzysztof ; Nowalany-Kozielska, Ewa ; Szyguła-Jurkiewicz, Bożena ; Nowak, Jolanta ; Poloński, Lech ; Dyrbuś, Krzysztof ; Badziński, Arkadiusz ; Mercik, Gabriela ; Zembala, Marian ; Wodniecki, Jan ; Rozek, Marius M.</creator><creatorcontrib>Wojnicz, Romuald ; Wilczek, Krzysztof ; Nowalany-Kozielska, Ewa ; Szyguła-Jurkiewicz, Bożena ; Nowak, Jolanta ; Poloński, Lech ; Dyrbuś, Krzysztof ; Badziński, Arkadiusz ; Mercik, Gabriela ; Zembala, Marian ; Wodniecki, Jan ; Rozek, Marius M.</creatorcontrib><description>This study evaluated the safety, tolerability, and efficacy of statin therapy in patients with heart failure secondary to inflammatory dilated cardiomyopathy and moderately elevated low-density lipoprotein cholesterol levels. Seventy-four patients were randomized to receive atorvastatin 40 mg/day or conventional treatment for heart failure. After 6 months of therapy, the predefined primary efficacy end point (an increase of >5% in the absolute left ventricular ejection fraction and ≥2 selected criteria by echocardiography and a decrease in New York Heart Association functional class) was significant in the statin-treated patients (p = 0.004). Among secondary efficacy parameters, the quality-of-life index showed a trend suggesting the benefit of statin therapy (p = 0.055). In conclusion, the results of this study demonstrate that treatment with atorvastatin in addition to standard therapy for heart failure may significantly improve clinical outcomes in this cohort of patients.</description><identifier>ISSN: 0002-9149</identifier><identifier>EISSN: 1879-1913</identifier><identifier>DOI: 10.1016/j.amjcard.2005.09.142</identifier><identifier>PMID: 16516598</identifier><identifier>CODEN: AJCDAG</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Adult ; Atorvastatin Calcium ; Biological and medical sciences ; Cardiology. Vascular system ; Cardiomyopathy, Dilated - complications ; Cardiomyopathy, Dilated - drug therapy ; Cholesterol ; Cholesterol, LDL - blood ; Cholesterol, LDL - drug effects ; Clinical outcomes ; Drug therapy ; Drug Therapy, Combination ; Endpoint Determination ; Evaluation Studies as Topic ; Female ; Heart ; Heart failure ; Heart Failure - drug therapy ; Heart Failure - etiology ; Heart failure, cardiogenic pulmonary edema, cardiac enlargement ; Heptanoic Acids - therapeutic use ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Hypercholesterolemia - complications ; Hypercholesterolemia - drug therapy ; Immunohistochemistry ; Low density lipoprotein ; Male ; Medical sciences ; Myocarditis. Cardiomyopathies ; Myocardium - pathology ; Pyrroles - therapeutic use ; Quality of Life ; Statins ; Treatment Outcome ; Ventricular Function, Left - drug effects</subject><ispartof>The American journal of cardiology, 2006-03, Vol.97 (6), p.899-904</ispartof><rights>2006 Elsevier Inc.</rights><rights>2006 INIST-CNRS</rights><rights>Copyright Elsevier Sequoia S.A. Mar 15, 2006</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c420t-e1fc5bd135393164eab848e5f2be246751d16d27d68d5ec367b0c2fc167c81373</citedby><cites>FETCH-LOGICAL-c420t-e1fc5bd135393164eab848e5f2be246751d16d27d68d5ec367b0c2fc167c81373</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.amjcard.2005.09.142$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17626424$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16516598$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wojnicz, Romuald</creatorcontrib><creatorcontrib>Wilczek, Krzysztof</creatorcontrib><creatorcontrib>Nowalany-Kozielska, Ewa</creatorcontrib><creatorcontrib>Szyguła-Jurkiewicz, Bożena</creatorcontrib><creatorcontrib>Nowak, Jolanta</creatorcontrib><creatorcontrib>Poloński, Lech</creatorcontrib><creatorcontrib>Dyrbuś, Krzysztof</creatorcontrib><creatorcontrib>Badziński, Arkadiusz</creatorcontrib><creatorcontrib>Mercik, Gabriela</creatorcontrib><creatorcontrib>Zembala, Marian</creatorcontrib><creatorcontrib>Wodniecki, Jan</creatorcontrib><creatorcontrib>Rozek, Marius M.</creatorcontrib><title>Usefulness of Atorvastatin in Patients With Heart Failure Due to Inflammatory Dilated Cardiomyopathy and Elevated Cholesterol Levels</title><title>The American journal of cardiology</title><addtitle>Am J Cardiol</addtitle><description>This study evaluated the safety, tolerability, and efficacy of statin therapy in patients with heart failure secondary to inflammatory dilated cardiomyopathy and moderately elevated low-density lipoprotein cholesterol levels. Seventy-four patients were randomized to receive atorvastatin 40 mg/day or conventional treatment for heart failure. After 6 months of therapy, the predefined primary efficacy end point (an increase of >5% in the absolute left ventricular ejection fraction and ≥2 selected criteria by echocardiography and a decrease in New York Heart Association functional class) was significant in the statin-treated patients (p = 0.004). Among secondary efficacy parameters, the quality-of-life index showed a trend suggesting the benefit of statin therapy (p = 0.055). In conclusion, the results of this study demonstrate that treatment with atorvastatin in addition to standard therapy for heart failure may significantly improve clinical outcomes in this cohort of patients.</description><subject>Adult</subject><subject>Atorvastatin Calcium</subject><subject>Biological and medical sciences</subject><subject>Cardiology. Vascular system</subject><subject>Cardiomyopathy, Dilated - complications</subject><subject>Cardiomyopathy, Dilated - drug therapy</subject><subject>Cholesterol</subject><subject>Cholesterol, LDL - blood</subject><subject>Cholesterol, LDL - drug effects</subject><subject>Clinical outcomes</subject><subject>Drug therapy</subject><subject>Drug Therapy, Combination</subject><subject>Endpoint Determination</subject><subject>Evaluation Studies as Topic</subject><subject>Female</subject><subject>Heart</subject><subject>Heart failure</subject><subject>Heart Failure - drug therapy</subject><subject>Heart Failure - etiology</subject><subject>Heart failure, cardiogenic pulmonary edema, cardiac enlargement</subject><subject>Heptanoic Acids - therapeutic use</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</subject><subject>Hypercholesterolemia - complications</subject><subject>Hypercholesterolemia - drug therapy</subject><subject>Immunohistochemistry</subject><subject>Low density lipoprotein</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Myocarditis. Cardiomyopathies</subject><subject>Myocardium - pathology</subject><subject>Pyrroles - therapeutic use</subject><subject>Quality of Life</subject><subject>Statins</subject><subject>Treatment Outcome</subject><subject>Ventricular Function, Left - drug effects</subject><issn>0002-9149</issn><issn>1879-1913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkV-L1DAUxYMo7jj6EZQg6Ftr_rRp-yTL7K67MKAPLj6GNLllUtJmTNKBefeDm2UKC74IF5JLfudwyEHoPSUlJVR8GUs1jVoFUzJC6pJ0Ja3YC7ShbdMVtKP8JdoQQljR0aq7Qm9iHPNKaS1eoysq6jxdu0F_HiMMi5shRuwHfJ18OKmYVLIzzvMjX2BOEf-y6YDvQYWE75R1SwB8swBOHj_Mg1PTpLLyjG-sUwkM3uVg1k9nf1TpcMZqNvjWwenydvAOYoLgHd7DCVx8i14NykV4t55b9Hh3-3N3X-y_f3vYXe8LXTGSCqCDrntDec07TkUFqm-rFuqB9cAq0dTUUGFYY0RratBcND3RbNBUNLqlvOFb9Pniewz-95IzyMlGDc6pGfwSpWiabMvbDH78Bxz9EuacTTJOuOBVTrBF9QXSwccYYJDHYCcVzpIS-dSRHOXakXzqSJJO5o6y7sNqvvQTmGfVWkoGPq2Ailq5IahZ2_jMNYKJilWZ-3rh8hfCyUKQUee2NBgbQCdpvP1PlL8mE7NT</recordid><startdate>20060315</startdate><enddate>20060315</enddate><creator>Wojnicz, Romuald</creator><creator>Wilczek, Krzysztof</creator><creator>Nowalany-Kozielska, Ewa</creator><creator>Szyguła-Jurkiewicz, Bożena</creator><creator>Nowak, Jolanta</creator><creator>Poloński, Lech</creator><creator>Dyrbuś, Krzysztof</creator><creator>Badziński, Arkadiusz</creator><creator>Mercik, Gabriela</creator><creator>Zembala, Marian</creator><creator>Wodniecki, Jan</creator><creator>Rozek, Marius M.</creator><general>Elsevier Inc</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TS</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>M7Z</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20060315</creationdate><title>Usefulness of Atorvastatin in Patients With Heart Failure Due to Inflammatory Dilated Cardiomyopathy and Elevated Cholesterol Levels</title><author>Wojnicz, Romuald ; Wilczek, Krzysztof ; Nowalany-Kozielska, Ewa ; Szyguła-Jurkiewicz, Bożena ; Nowak, Jolanta ; Poloński, Lech ; Dyrbuś, Krzysztof ; Badziński, Arkadiusz ; Mercik, Gabriela ; Zembala, Marian ; Wodniecki, Jan ; Rozek, Marius M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c420t-e1fc5bd135393164eab848e5f2be246751d16d27d68d5ec367b0c2fc167c81373</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adult</topic><topic>Atorvastatin Calcium</topic><topic>Biological and medical sciences</topic><topic>Cardiology. Vascular system</topic><topic>Cardiomyopathy, Dilated - complications</topic><topic>Cardiomyopathy, Dilated - drug therapy</topic><topic>Cholesterol</topic><topic>Cholesterol, LDL - blood</topic><topic>Cholesterol, LDL - drug effects</topic><topic>Clinical outcomes</topic><topic>Drug therapy</topic><topic>Drug Therapy, Combination</topic><topic>Endpoint Determination</topic><topic>Evaluation Studies as Topic</topic><topic>Female</topic><topic>Heart</topic><topic>Heart failure</topic><topic>Heart Failure - drug therapy</topic><topic>Heart Failure - etiology</topic><topic>Heart failure, cardiogenic pulmonary edema, cardiac enlargement</topic><topic>Heptanoic Acids - therapeutic use</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</topic><topic>Hypercholesterolemia - complications</topic><topic>Hypercholesterolemia - drug therapy</topic><topic>Immunohistochemistry</topic><topic>Low density lipoprotein</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Myocarditis. Cardiomyopathies</topic><topic>Myocardium - pathology</topic><topic>Pyrroles - therapeutic use</topic><topic>Quality of Life</topic><topic>Statins</topic><topic>Treatment Outcome</topic><topic>Ventricular Function, Left - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wojnicz, Romuald</creatorcontrib><creatorcontrib>Wilczek, Krzysztof</creatorcontrib><creatorcontrib>Nowalany-Kozielska, Ewa</creatorcontrib><creatorcontrib>Szyguła-Jurkiewicz, Bożena</creatorcontrib><creatorcontrib>Nowak, Jolanta</creatorcontrib><creatorcontrib>Poloński, Lech</creatorcontrib><creatorcontrib>Dyrbuś, Krzysztof</creatorcontrib><creatorcontrib>Badziński, Arkadiusz</creatorcontrib><creatorcontrib>Mercik, Gabriela</creatorcontrib><creatorcontrib>Zembala, Marian</creatorcontrib><creatorcontrib>Wodniecki, Jan</creatorcontrib><creatorcontrib>Rozek, Marius M.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Physical Education Index</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biochemistry Abstracts 1</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wojnicz, Romuald</au><au>Wilczek, Krzysztof</au><au>Nowalany-Kozielska, Ewa</au><au>Szyguła-Jurkiewicz, Bożena</au><au>Nowak, Jolanta</au><au>Poloński, Lech</au><au>Dyrbuś, Krzysztof</au><au>Badziński, Arkadiusz</au><au>Mercik, Gabriela</au><au>Zembala, Marian</au><au>Wodniecki, Jan</au><au>Rozek, Marius M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Usefulness of Atorvastatin in Patients With Heart Failure Due to Inflammatory Dilated Cardiomyopathy and Elevated Cholesterol Levels</atitle><jtitle>The American journal of cardiology</jtitle><addtitle>Am J Cardiol</addtitle><date>2006-03-15</date><risdate>2006</risdate><volume>97</volume><issue>6</issue><spage>899</spage><epage>904</epage><pages>899-904</pages><issn>0002-9149</issn><eissn>1879-1913</eissn><coden>AJCDAG</coden><abstract>This study evaluated the safety, tolerability, and efficacy of statin therapy in patients with heart failure secondary to inflammatory dilated cardiomyopathy and moderately elevated low-density lipoprotein cholesterol levels. Seventy-four patients were randomized to receive atorvastatin 40 mg/day or conventional treatment for heart failure. After 6 months of therapy, the predefined primary efficacy end point (an increase of >5% in the absolute left ventricular ejection fraction and ≥2 selected criteria by echocardiography and a decrease in New York Heart Association functional class) was significant in the statin-treated patients (p = 0.004). Among secondary efficacy parameters, the quality-of-life index showed a trend suggesting the benefit of statin therapy (p = 0.055). In conclusion, the results of this study demonstrate that treatment with atorvastatin in addition to standard therapy for heart failure may significantly improve clinical outcomes in this cohort of patients.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>16516598</pmid><doi>10.1016/j.amjcard.2005.09.142</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9149 |
| ispartof | The American journal of cardiology, 2006-03, Vol.97 (6), p.899-904 |
| issn | 0002-9149 1879-1913 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67716438 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Adult Atorvastatin Calcium Biological and medical sciences Cardiology. Vascular system Cardiomyopathy, Dilated - complications Cardiomyopathy, Dilated - drug therapy Cholesterol Cholesterol, LDL - blood Cholesterol, LDL - drug effects Clinical outcomes Drug therapy Drug Therapy, Combination Endpoint Determination Evaluation Studies as Topic Female Heart Heart failure Heart Failure - drug therapy Heart Failure - etiology Heart failure, cardiogenic pulmonary edema, cardiac enlargement Heptanoic Acids - therapeutic use Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Hypercholesterolemia - complications Hypercholesterolemia - drug therapy Immunohistochemistry Low density lipoprotein Male Medical sciences Myocarditis. Cardiomyopathies Myocardium - pathology Pyrroles - therapeutic use Quality of Life Statins Treatment Outcome Ventricular Function, Left - drug effects |
| title | Usefulness of Atorvastatin in Patients With Heart Failure Due to Inflammatory Dilated Cardiomyopathy and Elevated Cholesterol Levels |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T08%3A21%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Usefulness%20of%20Atorvastatin%20in%20Patients%20With%20Heart%20Failure%20Due%20to%20Inflammatory%20Dilated%20Cardiomyopathy%20and%20Elevated%20Cholesterol%20Levels&rft.jtitle=The%20American%20journal%20of%20cardiology&rft.au=Wojnicz,%20Romuald&rft.date=2006-03-15&rft.volume=97&rft.issue=6&rft.spage=899&rft.epage=904&rft.pages=899-904&rft.issn=0002-9149&rft.eissn=1879-1913&rft.coden=AJCDAG&rft_id=info:doi/10.1016/j.amjcard.2005.09.142&rft_dat=%3Cproquest_cross%3E67716438%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=230363439&rft_id=info:pmid/16516598&rft_els_id=S0002914905021211&rfr_iscdi=true |